Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Robert H. Vonderheide

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7252-954X; OpenAlex author ID A5040750947; NIH RePORTER profile ID 2052769. Sources: funder_awards.

Their work

Papers
32 (first author 4, last author 10)
Trials
1 (principal investigator on 1)
Grants
5
Labs led
1
Collaborators
95
Papers, trials and grants by year

2012: 1 paper · 2013: 3 papers, 1 grant · 2014: 1 trial · 2015: 1 paper · 2016: 2 papers, 1 grant · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 3 papers · 2021: 6 papers · 2022: 2 papers, 2 grants · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 4 papers, 1 grant

Papers 32

  1. Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Tria… Co-author DOI 10.1001/jamaoncol.2026.0870↗
  2. Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. Co-author DOI 10.1038/s41598-026-35423-7↗
  3. Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1126/science.aec7929↗
  4. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated m… Last author DOI 10.1136/jitc-2025-012864↗
  5. T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-24-1475↗
  6. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-49915-5↗
  7. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  8. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  9. Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0873↗
  10. Immune vulnerabilities of mutant KRAS in pancreatic cancer. First author DOI 10.1016/j.trecan.2023.07.004↗
  11. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1066↗
  12. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Last author DOI 10.1016/s1470-2045(22)00369-2↗
  13. Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE… Last author DOI 10.1038/s41591-022-01829-9↗
  14. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma… Last author DOI 10.1016/s1470-2045(20)30532-5↗
  15. Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-21-0612↗
  16. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-21-1047↗
  17. Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-20-0519↗
  18. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  19. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, B… Co-author DOI 10.1200/jco.21.00003↗
  20. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. First author DOI 10.1016/j.ccell.2020.08.004↗
  21. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3978↗
  22. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2020.605619↗
  23. Immunotherapy and Prevention of Pancreatic Cancer. Last author DOI 10.1016/j.trecan.2018.04.001↗
  24. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. Co-author DOI 10.1200/po.17.00316↗
  25. Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-16-2128↗
  26. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/2326-6066.cir-16-0188↗
  27. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. Last author DOI 10.1172/jci.insight.88328↗
  28. Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patient… Co-author DOI 10.1186/2051-1426-3-s2-p155↗
  29. CD40 immunotherapy for pancreatic cancer. Co-author DOI 10.1007/s00262-013-1427-5↗
  30. Cracking the stone: combination vaccination and CTLA-4 blockade in pancreatic cancer. First author DOI 10.1097/cji.0b013e31829fb7c8↗
  31. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-13-1320↗
  32. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Last author DOI 10.1016/j.ccr.2012.04.025↗

Trials 1

  1. hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Principal investigator NCT02960594↗

Grants 5

  1. Changing the natural history of pancreatic ductal adenocarcinoma with cancer interception strategies R01CA303474↗
  2. Project 1: Clinical and immune impact of radiation and dual checkpoint blockade in patients P01CA210944↗
  3. Molecular Determinants and Therapeutic Consequences of Immune Heterogeneity in Cancer R01CA229803↗
  4. Immunobiology and immunotherapy of pancreatic cancer R01CA169123↗
  5. Accelerating Development of CD40 Therapy for Pancreatic Cancer AWARD pancan:2013-robert-vonderheide-md-dphil-accelerating-development-of-cd40-therapy

Closest collaborators

The 25 strongest of 95 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ben Z. Stanger · 8 shared papers, 3 shared grants, 2012–2026 · strength 3.31
  2. Mark H. O’Hara · 9 shared papers, 2020–2026 · strength 1.30
  3. Kim A. Reiss · 7 shared papers, 2020–2026 · strength 1.24
  4. Andrew H. Ko · 6 shared papers, 2015–2026 · strength 0.67
  5. George Albert Fisher · 6 shared papers, 2015–2026 · strength 0.67
  6. Katelyn T. Byrne · 6 shared papers, 2016–2024 · strength 0.65
  7. Susan M. Domchek · 4 shared papers, 2018–2026 · strength 0.55
  8. Zev A. Wainberg · 4 shared papers, 2021–2026 · strength 0.54
  9. Robert A. Wolff · 4 shared papers, 2021–2026 · strength 0.54
  10. Eileen Mary O'Reilly · 4 shared papers, 2021–2026 · strength 0.54
  11. Noah C. Cheng · 2 shared papers, 2023 · strength 0.52
  12. Gregory Lawrence Beatty · 5 shared papers, 2012–2026 · strength 0.48
  13. Lacey Padrón · 3 shared papers, 2022–2026 · strength 0.45
  14. Lisa M. Coussens · 4 shared papers, 2020–2024 · strength 0.45
  15. Adham Sean Bear · 2 shared papers, 2020 · strength 0.43
  16. Thomas Benjamin Karasic · 3 shared papers, 2021–2024 · strength 0.38
  17. Max Miller Wattenberg · 2 shared papers, 2021–2026 · strength 0.37
  18. Andressa Dias Costa · 3 shared papers, 2021–2024 · strength 0.36
  19. Brian Matthew Wolpin · 3 shared papers, 2021–2024 · strength 0.36
  20. Jonathan Andrew Nowak · 3 shared papers, 2021–2024 · strength 0.36
  21. Samantha B. Kemp · 2 shared papers, 2023–2025 · strength 0.35
  22. Zain M. Hannan · 2 shared papers, 2021–2026 · strength 0.34
  23. Katherine L. Nathanson · 2 shared papers, 2021–2026 · strength 0.34
  24. Osama E. Rahma · 3 shared papers, 2021–2024 · strength 0.32
  25. Elizabeth M. Jaffee · 4 shared papers, 2015–2021 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.